Sponsor:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Code:
NCT04580420
Conditions
Primary Hyperoxaluria Type 1
End Stage Renal Disease
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
DCR-PHXC
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations